successfully used to express genes in eukaryotic cells. 4, 5 A variety of adenoviral gene therapy agents has been tested in various studies using in vitro and animal models. The tolerability, safety, and potential beneficial effects of these agents have been described for different target diseases 6, 7 however, the three-dimensional spread of replication-deficient adenoviruses after intratumoral administration might be less than ideal.
Oncolytic viruses that can selectively replicate in tumor cells and lyse infected cells have been extensively investigated as novel anticancer agents. 8, 9 These vectors are designed to induce virusmediated lysis of tumor cells after selective intracellular propagation while remaining innocuous to normal tissues. 10 The optimal treatment of human cancers requires improvement of the therapeutic ratio to increase the cytotoxicity to tumor cells and decrease that against normal cells. This may not be an easy task, because the majority of normal cells surrounding tumors are sensitive to cytotoxic agents. Thus, to establish reliable therapeutic strategies for human cancers, it is important to seek genetic and epigenetic targets present only in cancer cells. One targeting strategy involve the use of tissue-specific promoters to restrict gene expression or virus replication to specific tissues. A large number of different tissue-specific promoters such as prostate-specific antigen (PSA), 11 Mucin 1, 12 osteocalcin, 13 L-plastin, 14 midkine, 15 and E2F-1 16 have been used for virotherapy applications. However, for targeting tumors derived from various tissues, tumor-specific, rather than tissue-specific, promoters would be more advantageous. For example, the promoter for human telomerase reverse transcriptase (hTERT) is highly active in most tumor cells but inactive in normal somatic cells.
| TELOMER A S E AC TIVIT Y FOR TR ANSCRIP TIONAL C AN CER TARG E TING
One of the hallmarks of cancer is the unregulated proliferation of specific cell populations, which eventually affects normal cellular function throughout the body, and this is almost universally correlated with telomerase reactivation. Telomerase is a ribonucleoprotein complex that mediates the addition of TTAGGG repeats to the telomeric ends of chromosomes. The enzyme consists of three components: an RNA subunit (known as hTR, hTER, or hTERC),
17
telomerase-associated protein (hTEP1), 18 and the catalytic subunit (hTERT). 19, 20 Both hTR and hTERT are required for the reconstitution of telomerase activity in vitro 21 and thus represent the minimal catalytic core of telomerase in humans. 22 However, although hTR is widely expressed in embryonic and somatic tissues, hTERT expression is tightly regulated and not detectable in most somatic cells.
The strong association between telomerase activity and malignant tissues suggests that telomerase is a plausible target for the treatment of cancer. 23 Thus, the hTERT proximal promoter can be used as a molecular switch for the selective expression of target genes in tumor cells, as almost all advanced human cancer cells express telomerase, whereas most normal cells do not.
24,25

| G ENE TI C ENG INEERING OF AN HTERT PROMOTER-DRIVEN ON COLY TIC ADENOVIRUS
The use of modified adenoviruses that replicate and complete their lytic cycles preferentially in cancer cells is a promising strategy for the treatment of cancer. One approach to achieve tumor specificity of viral replication is based on the transcriptional control of genes that are critical for virus replication, such as E1A and E1B. The catalytic subunit of telomerase, hTERT, is expressed in the majority of human cancers, and the hTERT promoter is preferentially activated in a variety of human cancer cells. 26 Therefore, the hTERT promoter may be a suitable regulator of adenoviral replication. It was previously reported that transcriptional control of E1A expression by the hTERT promoter restricts adenoviral replication to telomerase-positive tumor cells, resulting in efficient lysis of the tumor cells.
27-30
We also examined the adenovirus E1B gene, which is expressed early in viral infection, and its gene product inhibits E1A-induced p53-dependent apoptosis, which in turn promotes the cytoplasmic accumulation of late viral messenger RNA (mRNA), leading to a shutdown of host cell protein synthesis. In most vectors that replicate under transcriptional control of the E1A gene, including hTERT-specific oncolytic adenoviruses, the E1B gene is driven by the endogenous adenovirus E1B promoter. However, it was previously reported that transcriptional control of both the E1A and E1B genes by a single tumor-specific promoter with the use of an internal ribosome entry site significantly improves the specificity and therapeutic index in particular human tumor cells. 31 Thus, we developed telomelysin (OBP-301), in which the tumor-specific hTERT promoter regulates expression of both the E1A
and E1B genes ( Figure 1 ). Telomelysin is expected to control viral replication more stringently, thereby providing greater therapeutic efficacy against tumor cells, as well as attenuated toxicity in normal tissues. 32 
| PRECLINI C AL S TUD IE S OF THE HTERT PROMOTER-DRIVEN ON COLY TIC ADENOVIRUS
In preclinical experiments, telomelysin-induced selective E1A and E1B expression in cancer cells, which resulted in virus replication at 5-6 logs by 3 days after infection, but telomelysin replication was attenuated up to 2 logs in cultured normal cells. 32 In vitro cytotoxicity assays demonstrated that telomelysin efficiently kills both epithelial and mesenchymal types of malignant tumor cells (including those of lung cancer, gastric cancer, esophageal cancer, colorectal cancer, head and neck cancer, hepatic cancer, cervical cancer, breast cancer, osteosarcoma, pancreas cancer, prostate cancer, melanoma, and mesothelioma) in a dose-dependent manner ( Figure 2 ). 33 In addition, intratumoral injection of telomelysin in subcutaneous and orthotopic xenograft tumor models was efficacious in treatment of both primary tumors 32, 34 and regional lymph node metastasis. 35, 36 Indeed, when telomelysin was intratumorally injected into human colorectal tumors orthotopically implanted into the rectum in nude mice, telomelysin caused viral spread into the regional lymphatic area and selectively replicated in neoplastic lesions, resulting in tumor cell-specific death in metastatic lymph nodes. 35 Thus, telomelysin not only exhibits features that make it desirable for use as an oncolytic therapeutic agent, the proportion of cancers potentially treatable using telomelysin is extremely high.
To further enhance the antitumor effect of telomelysin-based oncolytic virotherapy, we evaluated the therapeutic potential of telomelysin in combination with conventional radiotherapy. Ionizing radiation primarily induces double-strand breaks (DSBs) in DNA molecules.
Radiosensitization can result from a therapeutic increase in DNA DSBs or inhibition of their repair. The MRN complex, consisting of Mre11, Rad50, and NBS1, is quickly stimulated by DSBs and directly activates ataxia-telangiectasia mutated (ATM), an important signal transducer in the DNA damage repair response, which involves DNA repair and cell cycle checkpoints. 37 Therefore, defects in the MRN complex induce hypersensitivity to DNA damage. 38 We found that expression of the MRN complex in cancer cells decreased after telomelysin infection when E1B 55-kDa protein expression began, leading to inhibition of ATM phosphorylation by ionizing radiation and inhibition of DNA repair ( Figure 3 ). Telomelysin infection apparently sustains elevated levels of γH2AX (a hallmark of DNA DSBs) for longer periods in irradiated tumor cells. These findings indicate that tumor cells infected with telomelysin could be rendered sensitive to ionizing radiation. 39 
| CLINI C AL APPLI C ATI ON OF THE HTERT PROMOTER-DRIVEN ON COLY TIC ADENOVIRUS A S MONOTHER APY
Many clinical trials of adenoviruses testing their oncolytic properties are well underway (Table 1) . [40] [41] [42] [43] [44] To explore the clinical application All patients received telomelysin without dose-limiting toxicity.
Common grade 1 and 2 toxicities included injection site reactions (pain, induration) and systemic reactions (fever, chills). Pharmacokinetic and biodistribution data for telomelysin were of particular interest.
Circulating viral DNA was transiently (<6 h after injection) detected in plasma from 13 of 16 patients within 24 h after injection. This dosedependent initial peak in circulating virus titer was followed by a rapid decline; however, three patients demonstrated evidence of prolonged viral replication through detection of viral DNA in plasma on days 7 and 14, suggesting the replication of telomelysin in primary tumors. In one of these patients, the injected malignant lesion and loco-regional uninjected satellite nodules disappeared, fulfilling the definition of a complete response (CR) at day 28. Eleven patients satisfied RECIST criteria for stable disease response in the injected lesion at day 28, whereas three patients had progressive disease, and two patients were unevaluable. Six patients exhibited reductions in tumor size of 6.6%-33%, and one of these patients exhibited a 33% reduction in the size of the injected lesion at day 28 and 56.7% reduction at day 56. These clinical data suggest that telomelysin is well-tolerated and warrants further clinical studies of its use in treating solid cancers.
| MULTIDISCIPLINARY APPROACH US ING THE HTERT PROMOTER-DRIVEN ON COLY TIC ADENOVIRUS
The advantage of combination therapy with telomelysin plus conventional radiotherapy is that the areas in which each treatment demonstrates its F I G U R E 4 Schematic outline of strategies for treating esophageal cancer. A. Synopsis of the study design and objectives. B. Schematic illustration of the treatment schedule. Patients with esophageal cancer who are not eligible for standard treatments receive intratumoral needle injections of telomelysin on days 1, 18, and 32. Radiation therapy is administered concurrently over 6 weeks, beginning on day 4, up to a total of 60 Gy courses of endoscopic telomelysin injection in combination with radiotherapy is feasible and provides clinical benefits in patients with esophageal cancer, particularly those who are unfit for standard treatments.
| NE X T-G ENER ATI ON MULTIFUN C TIONAL HTERT PROMOTER-DRIVEN ON COLY TIC ADENOVIRUS
Oncolytic viruses armed to express several types of therapeutic transgenes have been reported. 48, 49 Among candidate therapeutic transgenes, the tumor suppressor p53 gene is particularly potent and exhibits a variety of effects, including induction of cell cycle arrest, apoptosis, senescence, and DNA repair. 50 Indeed, a p53-expressing replication-deficient adenovirus (Ad-p53, Advexin) was shown to induce antitumor effects both in vitro and in vivo, [51] [52] [53] as well as in various clinical studies. 54, 55 Therefore, to develop a next-generation hTERT promoter-driven oncolytic adenovirus, we modified telomelysin (OBP-301) to express the wild-type p53 tumor suppressor gene (OBP-702; Figure 1 ) and compared the antitumor activity of OBP-702 with that of telomelysin. 56, 57 The antitumor effects of OBP-702 and telomelysin were compared using telomelysin-sensitive and -resistant human cancer cells. 
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